TRIANNI Announces Partnering Agreement with Evotec

San Francisco, CA, USA., May 17, 2016 – Trianni, Inc. (“TRIANNI”) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809), today announced a partnering agreement that will allow Evotec access to the Trianni mice platform and enhance their portfolio of alliance and development partnerships.

“We are pleased to have Evotec as a partner,” stated Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. “With the Trianni Mouse platform’s distinctive features, most notably a full antibody repertoire expressed from chemically synthesized gene segments, we anticipate our platform will be a vital instrument for advancing Evotec’s turn-key solution for discovery of antibody therapeutics.”

Dr Mario Polywka, Chief Operating Officer of Evotec, stated: “We are happy to be chosen by Trianni as a preferred partner for antibody discovery services. The Trianni Mouse embodies a next-generation technology to develop fully human monoclonal antibodies and it is now an integral component of our service portfolio. It will complement our existing drug discovery platforms and we look forward to enabling exciting new projects and more value to joint clients.”

No financial details were disclosed.

About Trianni, Inc.

Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit

About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute).The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer’s disease, with MedImmune and Sanofi in the field of diabetes, with Pfizer in the field of organ fibrosis and with Second Genome in the field of inflammatory diseases. For additional information please go to

Contacts- TRIANNI
Mandy Boyd
Director of Marketing
1.415.231.0256 [o]

Contacts- Evotec AG
Hermann-Josef Kaiser, PhD
Business Development Manager

Florence Eustache, PhD
Business Development Executive
+44. (0)1235 441250 (Direct)